ERBB2 and osteosarcoma: Trastuzumab, an anti-human HER2 monoclonal antibody used to treat HER2-positive breast cancer and HER2-positive osteosarcoma in pediatric populations, did not significantly improve overall survival of osteosarcoma in children and was associated with the potential for cardiotoxicity [35].